62
Views
0
CrossRef citations to date
0
Altmetric
Miscellaneous

Semisynthetic derivatives of mannopeptimycin antibiotics active against multi-drug resistant Gram-positive bacteria

Pages 1299-1303 | Published online: 02 Mar 2005

Bibliography

  • RYBAK M: Therapeutic options for Gram-positive infections. .J. Hosp. Infect. (2001) 49 (Suppl.A) : S25–532.
  • DIEKEMA DJ, JONES RN: Oxazolidinone antibiotics. Lancet (2001) 358:1975–1982.
  • SMITH TL, PEARSON ML, WILCOX KR et al: Emergence of vancomycin resistance in Staphylococcus aureus. N Engl. I Med. (1999) 340:493–501.
  • PERL TM: The threat of vancomycin resistance. Am. J. Med. (1999) 106(5A):265-375 and 48S–52S.
  • HIRAMATSU K: The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. Am. J. Med. (1998) 104:7S–10S.
  • TENOVER FC, LANCASTER MV, HILL BC et al: Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. ./. Clin. Microbial. (1998) 36:1020–1027.
  • THORNSBERRY C, SAHM DF, KELLY LJ et al: Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumaniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST surveillance program, 1999–2000. Clin. Infect. Dis. (2002) 34\(Supp1.1):54–516.
  • LINDEN PK: Treatment options for vancomycin-resistant enterococcal infections. Drugs (2002) 62(3):425–441.
  • ABBANAT D, MACIELAG M, BUSH K: Novel antibacterial agents for the treatment of serious Gram-positive infections. Expert Opin. Investig. Drugs (2003) 12(3):379–399.
  • ••An excellent review on new developmentalanti-Gram-positive agents currently undergoing clinical trials in humans.
  • SING MP, JANSO JE, LUCKMAN SW, GREENSTEIN M: AC98, new cyclic glycopeptide antibiotics: mechanism of action. Abstracts of 41st Intersci. Conf Antimicrob. Agents Chemother. (2001) F-1149:230.
  • DUSHIN RG, WANG T, FORTIER G et al: Synthesis of AC98-6446, a semisynthetic mannopeptimycin derivative. Abstracts of 42nd Intersci. Conf Antimicrob. Agents Chemother. (2002) F-352:179.
  • PETERSEN PJ, LABTHAVIKUL P, WANG T, DUSHIN RG, BRADFORD P: In vitro comparative activity of AC98-6446, a novel semisynthetic cyclic glycopeptide derivative of the natural product AC98-1, and other antimicrobial agents against Gram-positive clinical isolates. Abstracts of 42nd Intersci. Conf. Antimicrob. Agents Chemother. (2002) F-353:179.
  • PETERSEN PJ, HARTMAN H, WANG T, DUSHIN RG, BRADFORD P: Time kill kinetics and postantibiotic effects (PAE) of the AC98 novel semisynthetic cyclic glycopeptide antibiotic derivative AC98-6446. Abstracts of 42nd Intersci. Conf Antimicrob. Agents Chemother. (2002) F-354:179.
  • LABTHAVIKUL P, PETERSEN PJ, WANG TZ, DUSHIN RG, BRADFORD PA: Effect of inoculum, pH and biofilm on the in vitro activity of AC98-6446 the novel semi-synthetic cyclic glycopeptide of AC98. Abstracts of 42nd Intersci. Conf Antimicrob. Agents Chemother. (2002) F-355:179.
  • MURPHY TM, LENOY EB, YOUNG M, WEISS WJ: In vivo efficacy and pharmacokinetics of AC98-6446, a novel cyclic glycopeptide, in experimental models of infection. Abstracts of 42nd Intersci. Conf Antimicrob. Agents Chemother. (2002) F-356:180.
  • HE H, WILLIAMSON RT, SHEN B et al.:Mannopeptimycins, novel antibacterial glycopeptides from Streptomyces hygrascopicus, LL-AC98. J. Am. Chem. Soc. (2002) 124:9729–9736.
  • MALABARBA A, CIABATTI R: Glycopeptide derivatives. Curr. Med. Chem. (2001) 8:1759–1773.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.